Baillie Gifford & CO Vertex Pharmaceuticals Inc Transaction History
Baillie Gifford & CO
- $126 Billion
- Q2 2024
A detailed history of Baillie Gifford & CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Baillie Gifford & CO holds 167,616 shares of VRTX stock, worth $79.5 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
167,616Holding current value
$79.5 Million% of portfolio
0.06%Shares
10 transactions
Others Institutions Holding VRTX
# of Institutions
1,707Shares Held
226MCall Options Held
1.2MPut Options Held
1.59M-
Capital World Investors Los Angeles, CA26.7MShares$12.7 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$10.9 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.1 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.56 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$4.05 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $122B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...